MiNK Therapeutics (INKT) director granted 975 RSUs, ownership 17,908

MiNK Therapeutics director Robert Peter Kadlec was granted 975 restricted stock units (RSUs) as board and committee compensation on 09/02/2025.

Rhea-AI Filing Summary

MiNK Therapeutics director Robert Peter Kadlec was granted 975 restricted stock units (RSUs) as board and committee compensation on 09/02/2025. The RSUs, received in lieu of cash retainers, represent a contingent right to one share of common stock per RSU and will vest one month from the grant date. Following the award, the reporting person beneficially owns 17,908 shares. The transaction is reported on Form 4 for ticker INKT and was signed by an attorney-in-fact on 09/03/2025.

Positive

• 975 RSUs granted to Director Robert Peter Kadlec as compensation, increasing his beneficial ownership to 17,908 shares
• RSUs vest in one month, creating a clear and short alignment period between the director and shareholders
• Award received in lieu of cash retainers, indicating equity-based compensation rather than cash expense

Negative

• None.

Insights

Financial Analyst

TL;DR Routine director equity award; increases insider alignment with shareholders without indicating material change to company finances.

The grant of 975 RSUs to a director is a standard governance practice to compensate and align directors with shareholder interests. The RSUs convert to common shares on vesting, increasing the reporting persons beneficial ownership to 17,908 shares. There is no cash outlay by the company reported here and no indication of a large, dilutive issuance from the information provided. This Form 4 discloses insider compensation rather than operational or financial performance changes.

Corporate Governance Expert

TL;DR Typical board compensation disclosed; vesting within one month is specified and straightforward.

The filing documents that RSUs were awarded in lieu of cash retainers for board and committee work and will vest one month after grant. This is a customary disclosure under Section 16 reporting rules and suggests timely reporting and standard insider compensation practice. No unusual terms, accelerated vesting, or related-party arrangements are disclosed in this Form 4.

Insider Trade Summary

Grant/Award: 975 shares

Grant/Award 1 txn

Insider Kadlec Robert Peter

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	975	$13.86	$14K

Holdings After Transaction: Common Stock — 17,908 shares (Direct)

Footnotes (1)

1. F1. The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Common Stock for each RSU. The RSUs were received in lieu of cash retainers for board and committee compensation. The RSUs will vest one month from the grant date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did the Form 4 for MiNK Therapeutics (INKT) report?

The Form 4 reports that director Robert Peter Kadlec was granted 975 RSUs on 09/02/2025, increasing his beneficial ownership to 17,908 shares.

What are the terms of the RSU grant disclosed on the INKT Form 4?

The RSUs represent a contingent right to one share per RSU, were granted in lieu of cash retainers, and will vest one month from the grant date.

Was a cash payment made for the RSU award reported on the Form 4?

No cash payment is reported; the RSUs were received in lieu of cash retainers as stated in the filing.

When was the Form 4 for this transaction signed and filed?

The signature on the form was executed by an attorney-in-fact on 09/03/2025 as shown in the filing.

Does the Form 4 indicate any derivative transactions for INKT by the reporting person?

No derivative securities transactions are disclosed in the provided Table II content of this Form 4.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 09/03/2025 - 05:30 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kadlec Robert Peter

(Last) (First) (Middle)

149 FIFTH AVENUE, SUITE 500

(Street)

NEW YORK NY 10010

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
MiNK Therapeutics, Inc. [ INKT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
09/02/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/02/2025		A		975	A	$13.86(1)	17,908	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Common Stock for each RSU. The RSUs were received in lieu of cash retainers for board and committee compensation. The RSUs will vest one month from the grant date.

	By: /s/ Christine Klaskin, Attorney-in-Fact	09/03/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.